Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has earned a consensus rating of “Hold” from the twenty-two brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $29.79.
RARE has been the topic of several recent research reports. William Blair raised Ultragenyx Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Citigroup lowered their price objective on shares of Ultragenyx Pharmaceutical from $32.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Bank of America cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a research note on Thursday, September 3rd. Wells Fargo & Company lifted their price objective on shares of Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. Finally, Guggenheim reduced their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th.
Get Our Latest Stock Report on RARE
Insider Activity
In other news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer owned 89,229 shares in the company, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is owned by company insiders.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $355,746,000. Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $38,347,000. GW&K Investment Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 55.8% during the 3rd quarter. GW&K Investment Management LLC now owns 2,307,844 shares of the biopharmaceutical company’s stock worth $34,687,000 after purchasing an additional 826,666 shares during the period. Jefferies Financial Group Inc. bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $31,040,000. Finally, Eagle Health Investments LP bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $29,521,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.
Ultragenyx Pharmaceutical Price Performance
Shares of RARE stock traded down $0.19 during trading hours on Friday, hitting $16.08. The stock had a trading volume of 1,679,424 shares, compared to its average volume of 3,590,241. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -3.10 and a beta of 0.37. Ultragenyx Pharmaceutical has a one year low of $12.73 and a one year high of $39.89. The stock’s 50-day moving average price is $15.29 and its two-hundred day moving average price is $22.52.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The company had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. The company’s revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.81) earnings per share. As a group, equities research analysts predict that Ultragenyx Pharmaceutical will post -3.21 earnings per share for the current fiscal year.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
See Also
- Five stocks we like better than Ultragenyx Pharmaceutical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
